Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.
Amgen's announcement that its drug, when combined with AstraZeneca's immunotherapy, reduces the risk of death by 58% in patients with aggressive lung cancer is a significant development in the oncology space. This data suggests that the combination therapy has the potential to become a new standard of care for this patient population, which currently has limited treatment options.
The aggressive form of lung cancer, also known as non-small cell lung cancer (NSCLC), is a major area of focus for pharmaceutical companies, with several players investing heavily in research and development. The fact that Amgen's drug, when added to AstraZeneca's immunotherapy, can improve overall survival rates by such a substantial margin is likely to make it an attractive treatment option for patients and healthcare providers.
To watch next: The next step will be to see if regulatory agencies approve the combination therapy and if it can be effectively commercialized. Additionally, investors will be monitoring Amgen's and AstraZeneca's future earnings reports to gauge the potential market share and revenue impact of this new treatment option. It will also be interesting to see how other pharmaceutical companies with lung cancer treatments respond to this development and if they have any competing therapies in their pipelines.
Originally reported by cnbc.com. Trade-News adds analysis for finance & markets readers.